We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease (EXPEDITION EXT)

This study has been terminated.
(Solanezumab did not meet the primary endpoint in study H8A-MC-LZAX.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01127633
First Posted: May 21, 2010
Last Update Posted: March 8, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Eli Lilly and Company
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2017
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Submission: September 29, 2014